ClinicalTrials.gg
Not yet recruitingNCT07946874Updated Nov 18, 2026

Dexamethasone Added to Transversalis Fascia Plane Block in Inguinal Hernia Repair

An interventional study of Dexamethasone and Bupivacaine in Inguinal Hernia Unilateral, Postoperative Pain and Transversalis Fascia Plane Block, sponsored by Sivas Numune Hospital. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Sivas Numune Hospital · Not applicable, Interventional, and Treatment

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 149 studies testing dexamethasone in Pain, Postoperative — 28 open to participants now, 31 under way, 2 of them phase 3. Dexamethasone · Pain, Postoperative.

Planned enrollment
98th of 149
64 · median 88
Started
2026
with 17 others
No phase
38 of 149
7 open now
Primary completion
2027-02
later than 21 of 30 live
Registered
149th of 149
by date

Among the 149 studies testing dexamethasone in Pain, Postoperative, this one is the 98th largest by planned enrollment, is one of 18 that started in 2026, is one of 38 with no phase, reaches primary completion later than 21 of the 30 other live ones, and was the 149th registered.

Pain, Postoperative

5,671 studies on the registry are indexed under Pain, Postoperative; 1,238 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

28 of the 149 studies testing dexamethasone in Pain, Postoperative are open now, in 8 countries. Recruiting first, the newest first:

22 more — sign in →

By country, each count listing its studies:

All 28 open studies →

About dexamethasone

Dexamethasone: first FDA approval 1958 (DECADRON), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 240 (35%) set no upper age limit and 328 (48%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 149 studies testing dexamethasone in Pain, Postoperative, or all of them as a file.
02

Study summary

Transversalis fascia plane (TFP) block is an ultrasound-guided abdominal wall block used for postoperative analgesia after inguinal hernia repair. Perineural dexamethasone prolongs analgesia in peripheral nerve blocks, but its efficacy in fascial plane blocks, where the injectate reaches the nerves by diffusion, is uncertain, and no placebo-controlled randomized trial has addressed this question for the TFP block. This prospective, randomized, controlled, double-blind trial will evaluate whether adding 4 mg dexamethasone to bupivacaine in a TFP block prolongs the time to first analgesic request and reduces rescue analgesic consumption in adult patients undergoing elective unilateral open inguinal hernia repair under spinal anesthesia. Sixty-four patients will be randomized 1:1 to bupivacaine + dexamethasone or bupivacaine + saline.

Read the detailed description

Patients scheduled for elective unilateral open inguinal hernia repair under spinal anesthesia (15 mg hyperbaric bupivacaine 0.5%) will be randomized to two groups (n=32 each) using computer-generated random numbers (Research Randomizer). At the end of surgery, a unilateral ultrasound-guided TFP block will be performed (in-plane technique, 21G 100 mm needle, between the transversus abdominis muscle and the transversalis fascia, between the midaxillary line and the iliac crest).

Group D: 20 mL 0.25% bupivacaine + 4 mg (1 mL) dexamethasone. Group K (control): 20 mL 0.25% bupivacaine + 1 mL saline. Total volume is 21 mL in both groups. Study solutions are prepared by an independent anesthesia technician not otherwise involved in the study. The block performer, the postoperative assessor and the patient are blinded to group allocation.

All patients receive 1 g IV paracetamol 20 minutes before the end of surgery and 1000 mg IV paracetamol every 8 hours postoperatively. Rescue analgesia: 50 mg IV dexketoprofen for NRS ≥4 or on patient request; if NRS remains ≥4, 50 mg IV tramadol. Pain (NRS) is assessed at rest and during movement at 2, 4, 8, 12 and 24 hours. Recovery quality is assessed with the Turkish version of the QoR-15 (QoR-15T) preoperatively and at 24 hours. Block-related complications are monitored.

Sample size (G*Power 3.1.9.4; d=0.75, alpha 0.05 two-tailed, power 80%) was 29 per group; increased by 10% for dropouts to 32 per group (N=64). Data will be analyzed with SPSS 23.0 (independent t-test or Mann-Whitney U for continuous variables, chi-square or Fisher's exact test for categorical variables; p\<0.05).

03

Conditions studied

  • Inguinal Hernia Unilateral
  • Postoperative Pain
  • Transversalis Fascia Plane Block

Browse trials for

Keywords

  • Transversalis fascia plane block
  • Dexamethasone
  • Adjuvant
  • Postoperative analgesia
  • Regional anesthesia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • I-II
  • Elective unilateral open inguinal hernia repair under spinal anesthesia
  • Written

Exclusion criteria

Exclusion Criteria:

  • Infection at the block site
  • Known allergy or to local anesthetics or dexamethasone
  • History of bleeding diathesis or coagulopathy
  • Uncontrolled diabetes mellitus
  • Severe cognitive impairment preventing pain assessment (NRS)
  • Refusal or inability to give
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
64 participants (estimated)

Study arms

  • Experimental
    Grup D

    TFP block with 20 mL 0.25% bupivacaine + 4 mg (1 mL) dexamethasone (total 21 mL) at the end of surgery.

    Drug: Dexamethasone · Drug: Bupivacaine

  • Placebo comparator
    Grup K

    TFP block with 20 mL 0.25% bupivacaine + 1 mL 0.9% saline (total 21 mL) at the end of surgery.

    Drug: Bupivacaine · Drug: 0.9 % sodium chloride

Interventions

  • 4 mg (1 mL) added to bupivacaine in the TFP block.

  • 20 mL 0.25% bupivacaine for the TFP block.

  • Drug0.9 % sodium chloride

    1 mL 0.9% saline added to bupivacaine as placebo.

06

What researchers measure

Primary outcomes

  1. Time to first analgesic request

    Time in minutes from completion of the TFP block to the first request for rescue analgesia (dexketoprofen 50 mg IV), given for NRS ≥4 or on patient request.

    Time frame: 24 hours postoperatively

Secondary outcomes

  1. VAS pain score at rest

    Pain intensity at rest measured with the Visual Analog Scale (VAS, 0 = no pain, 10 = worst imaginable pain).

    Time frame: 2, 4, 8, 12 and 24 hours postoperatively

  2. VAS pain score during movement

    Pain intensity during movement (coughing or 30° leg raise) measured with the VAS (0-10).

    Time frame: 2, 4, 8, 12 and 24 hours postoperatively

07

Study locations

1 site
08

References and documents

Publications

  • Celik HK, Tulgar S, Buk OF, Koc K, Unal M, Genc C, Suren M. Comparison of the analgesic efficacy of the ultrasound-guided transversalis fascia plane block and erector spinae plane block in patients undergoing open inguinal hernia repair under spinal anesthesia. Korean J Anesthesiol. 2024 Apr;77(2):255-264. doi: 10.4097/kja.23404. Epub 2024 Jan 8. PubMed 38185619 ↗
  • Hebbard PD. Transversalis fascia plane block, a novel ultrasound-guided abdominal wall nerve block. Can J Anaesth. 2009 Aug;56(8):618-20. doi: 10.1007/s12630-009-9110-1. Epub 2009 Jun 4. No abstract available. PubMed 19495909 ↗

Individual participant data

Plan to share: No — upon reasonable request

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Feb 2027, 2 months later.

Of 2,101 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 2 months is below that.

Counting every sponsor, half of 2,114 studies reached it within 11 months; a quarter within 6 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2026
First posted
Nov 18, 2026
StartEst.
Nov 22, 2026
Primary completionEst.
Feb 1, 2027
CompletionEst.
Feb 1, 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07946874
Lead sponsor
Sivas Numune Hospital
Responsible party
Fatih Balcı (Specialist Physician, Department of Anesthesiology and Reanimation, Sivas Numune Hospital) — Principal investigator
First posted
Nov 18, 2026
Start date
Nov 22, 2026 (estimated)
Primary completion
Feb 1, 2027 (estimated)
Completion
Feb 1, 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Fatih Balcı
Contact
fatihbalci05@gmail.com
+90 545 864 76 57

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexamethasone

Start the discussion